- Home
- WNW vs CLNN Comparison
WNW vs CLNN Comparison
Compare WNW & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- CLNN
- Stock Information
- Founded
- WNW 2015
- CLNN 2012
- Country
- WNW China
- CLNN United States
- Employees
- WNW N/A
- CLNN N/A
- Industry
- WNW Catalog/Specialty Distribution
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- WNW Consumer Discretionary
- CLNN Health Care
- Exchange
- WNW Nasdaq
- CLNN Nasdaq
- Market Cap
- WNW 49.2M
- CLNN 43.0M
- IPO Year
- WNW 2020
- CLNN N/A
- Fundamental
- Price
- WNW $1.64
- CLNN $4.34
- Analyst Decision
- WNW
- CLNN Strong Buy
- Analyst Count
- WNW 0
- CLNN 4
- Target Price
- WNW N/A
- CLNN $55.25
- AVG Volume (30 Days)
- WNW 378.6K
- CLNN 121.1K
- Earning Date
- WNW 12-31-2024
- CLNN 11-13-2024
- Dividend Yield
- WNW N/A
- CLNN N/A
- EPS Growth
- WNW N/A
- CLNN N/A
- EPS
- WNW N/A
- CLNN N/A
- Revenue
- WNW $380,345.00
- CLNN $421,000.00
- Revenue This Year
- WNW N/A
- CLNN N/A
- Revenue Next Year
- WNW N/A
- CLNN N/A
- P/E Ratio
- WNW N/A
- CLNN N/A
- Revenue Growth
- WNW N/A
- CLNN N/A
- 52 Week Low
- WNW $0.71
- CLNN $3.82
- 52 Week High
- WNW $11.11
- CLNN $12.00
- Technical
- Relative Strength Index (RSI)
- WNW 75.09
- CLNN 44.40
- Support Level
- WNW $0.91
- CLNN $4.22
- Resistance Level
- WNW $1.68
- CLNN $5.47
- Average True Range (ATR)
- WNW 0.15
- CLNN 0.45
- MACD
- WNW 0.05
- CLNN 0.06
- Stochastic Oscillator
- WNW 78.63
- CLNN 30.57
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).